Sens. Manchin, Braun Introduce Bipartisan Bill to Address Gaps in Opioid Approval Process
May 27, 2022
May 27, 2022
WASHINGTON, May 27 -- Sen. Joe Manchin, D-West Virginia, issued the following news release:
U.S. Senators Joe Manchin (D-WV) and Mike Braun (R-IN) introduced the Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement (EFFECTIVE) Act which would allow the Food and Drug Administration (FDA) to deny a new drug application for an opioid analgesic drug on the basis of the drug not being clinically superior to other commercially available drugs. FDA Commiss . . .
U.S. Senators Joe Manchin (D-WV) and Mike Braun (R-IN) introduced the Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement (EFFECTIVE) Act which would allow the Food and Drug Administration (FDA) to deny a new drug application for an opioid analgesic drug on the basis of the drug not being clinically superior to other commercially available drugs. FDA Commiss . . .